Skip to main content
Sai Life Sciences Limited logo

Sai Life Sciences Limited — Investor Relations & Filings

Ticker · SAILIFE ISIN · INE570L01029 LEI · 335800JBS3NY25NIBC93 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 233 across all filing types
Latest filing 2026-03-21 Regulatory Filings
Country IN India
Listing BSE.NS SAILIFE

About Sai Life Sciences Limited

https://www.sailife.com

Sai Life Sciences Limited is a full-service Contract Research, Development, and Manufacturing Organization (CRO-CDMO) that partners with global pharmaceutical and biotechnology innovators to accelerate the discovery, development, and commercialization of complex small molecules. The company provides an integrated platform of services spanning discovery chemistry and biology, DMPK, toxicology, process development, analytical R&D, and commercial-scale manufacturing. With a focus on operational excellence and regulatory compliance, it operates state-of-the-art R&D and manufacturing facilities. Its value proposition centers on the Sai Nxt initiative, which emphasizes investments in advanced technologies, expanded capacity, and a global delivery model designed to reduce time-to-market for novel therapeutics.

Recent filings

Filing Released Lang Actions
Action(s) initiated or orders passed
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports an order passed by the Deputy Commissioner of Income Tax regarding non-deduction of TDS on payments to non-residents, including details of tax, interest, and potential penalty amounts. The document includes a detailed annexure with specifics of the order, litigation details, and expected financial impact. There are no financial statements or comprehensive financial data presented, nor is this a report like an annual or interim report. The document is a regulatory announcement about a legal/tax matter affecting the company, fitting the description of a Regulatory Filing (RNS) as it is a compliance disclosure under SEBI regulations and does not fit other categories such as Legal Proceedings Report (LTR) because it is a regulatory disclosure under Listing Regulations. The document length is about 5452 characters, which is sufficient for a detailed regulatory announcement but not a full report. Therefore, the best classification is Regulatory Filings (RNS).
2026-03-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated 07 March 2026 informing stock exchanges about a scheduled meeting with analysts/investors. It explicitly states that no new presentation will be made and that no unpublished price sensitive information will be discussed. The document is an intimation or announcement of a meeting schedule rather than a financial report, earnings release, or presentation. It does not contain financial data, results, or detailed analysis. The length is only 1992 characters, which is short and typical for a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-07 English
Credit Rating- New
Capital/Financing Update Classification · 95% confidence The document is a letter from Sai Life Sciences Limited to stock exchanges regarding a credit rating issued by ICRA Limited. It details the assigned credit ratings for various financial instruments and includes a table of bank limits rated. The document is an intimation under SEBI regulations about the credit rating action, not a financial report or audit. It does not contain financial statements or detailed financial analysis but is an update on the company's credit rating status. This fits the category of Capital/Financing Update (CAP), as it relates to the company's financing instruments and creditworthiness. The document length is 7496 characters, sufficient for a detailed update but not a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2026-02-26 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is an official intimation to stock exchanges (BSE and NSE) regarding the allotment of equity shares under the company's Employees Stock Option Plans (ESOP 2008 and MESOP 2018). It details the number of shares allotted, exercise prices, dates, and regulatory references under SEBI regulations. The document is a regulatory disclosure about share allotment following the exercise of stock options, which is a capital change event. It is not a full financial report, earnings release, or management discussion. It is not a report publication announcement or a certification. The content fits the category of Share Issue/Capital Change announcements, as it informs about new shares issued due to ESOP exercises and the resulting changes in share capital. The document length (9599 characters) and detailed annexures support this classification with high confidence.
2026-02-26 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the allotment of equity shares under Employees Stock Option Plans (ESOP 2008 and MESOP 2018). It provides detailed disclosures as required under SEBI regulations, including the number of shares allotted, exercise price, premium per share, and other regulatory details. The document is an intimation or announcement of the allotment of shares following the exercise of stock options, which is a capital change event. It does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. The document fits the category of a Share Issue/Capital Change announcement as it informs about new shares issued due to ESOP exercises.
2026-02-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of meetings with analysts and investors. It explicitly states that no new presentation will be made and that the company does not intend to discuss unpublished price sensitive information. The document is an announcement of upcoming investor meetings rather than a detailed investor presentation or financial report. It is also under 5,000 characters and serves as a regulatory disclosure of scheduled meetings, fitting best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Investor Presentation (IP) or other report type.
2026-02-17 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.